{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:05:36Z","timestamp":1782093936320,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02721-5","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:06:10Z","timestamp":1747735570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ticagrelor inhibits the growth of lung adenocarcinoma by downregulating SYK expression and modulating the PI3K\/AKT pathway"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuanhong","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanhui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"2721_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.canlet.2020.08.013","volume":"492","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. CircRNAs in lung cancer\u2014Biogenesis, function and clinical implication. Cancer Lett. 492, 106\u2013115 (2020).","journal-title":"Cancer Lett."},{"issue":"1","key":"2721_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade, B. C. & Dela Cruz, C. S. Lung cancer 2020: Epidemiology, etiology, and prevention. Clin. Chest Med. 41(1), 1\u201324 (2020).","journal-title":"Clin. Chest Med."},{"issue":"7689","key":"2721_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553(7689), 446\u2013454 (2018).","journal-title":"Nature"},{"issue":"Supplementum 1","key":"2721_CR4","first-page":"43","volume":"34","author":"D Krej\u010d\u00ed","year":"2021","unstructured":"Krej\u010d\u00ed, D., T\u0159ebick\u00fd, F., Fanta, J., Op\u00e1lka, P. & Pauk, N. New treatment modalities in the early stage and locally advanced non-small cell lung cancer. Klin. Onkol. 34(Supplementum 1), 43\u201347 (2021).","journal-title":"Klin. Onkol."},{"issue":"1","key":"2721_CR5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1119\/1.2359002","volume":"75","author":"LG Collins","year":"2007","unstructured":"Collins, L. G., Haines, C., Perkel, R. & Enck, R. E. Lung cancer: Diagnosis and management. Am. Fam. Phys. 75(1), 56\u201363 (2007).","journal-title":"Am. Fam. Phys."},{"issue":"2","key":"2721_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11(2), 121\u2013128 (2010).","journal-title":"Lancet Oncol."},{"issue":"9","key":"2721_CR7","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","volume":"26","author":"C Zhou","year":"2015","unstructured":"Zhou, C. et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann. Oncol. 26(9), 1877\u20131883 (2015).","journal-title":"Ann. Oncol."},{"issue":"2","key":"2721_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.31083\/j.rcm2202044","volume":"22","author":"NC Sanderson","year":"2021","unstructured":"Sanderson, N. C., Parker, W. A. E. & Storey, R. F. Ticagrelor: clinical development and future potential. Rev. Cardiovasc. Med. 22(2), 373\u2013394 (2021).","journal-title":"Rev. Cardiovasc. Med."},{"issue":"2","key":"2721_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/00015385.2018.1469371","volume":"74","author":"RA Guerbaai","year":"2019","unstructured":"Guerbaai, R. A., Mahata, I., Mar\u00e9chaux, S., Le Jemtel, T. H. & Ennezat, P. V. Is ticagrelor worth its high cost and side-effects?. Acta Cardiol. 74(2), 93\u201398 (2019).","journal-title":"Acta Cardiol."},{"issue":"4","key":"2721_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11302-022-09888-w","volume":"18","author":"P Vargas","year":"2022","unstructured":"Vargas, P. et al. P2Y(12) receptor antagonism inhibits proliferation, migration and leads to autophagy of glioblastoma cells. Purinergic Signal 18(4), 481\u2013494 (2022).","journal-title":"Purinergic Signal"},{"key":"2721_CR11","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.3390\/ijms21218177","volume":"21","author":"P Nata\u0161a","year":"2020","unstructured":"Nata\u0161a, P., Maria, K., P\u00e4r, G. & Femke, H. Inhibiting P2Y12 in macrophages induces endoplasmic reticulum stress and promotes an anti-tumoral phenotype. Int. J. Mol. Sci. 21, 8177 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2721_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cpt.3067","volume":"115","author":"M Lehtisalo","year":"2024","unstructured":"Lehtisalo, M. et al. Ticagrelor increases exposure to the breast cancer resistance protein substrate rosuvastatin. Clin. Pharmacol. Ther. 115(1), 71\u201379 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"2721_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","volume":"10","author":"A M\u00f3csai","year":"2010","unstructured":"M\u00f3csai, A., Ruland, J. & Tybulewicz, V. L. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat. Rev. Immunol. 10(6), 387\u2013402 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"2721_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117514","volume":"96","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK). Bioorg. Med. Chem. 96, 117514 (2023).","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"2721_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/ijms18061238","volume":"18","author":"R Badolia","year":"2017","unstructured":"Badolia, R., Kostyak, J. C., Dangelmaier, C. & Kunapuli, S. P. Syk activity is dispensable for platelet GP1b-IX-V signaling. Int. J. Mol. Sci. 18(6), 1238 (2017).","journal-title":"Int. J. Mol. Sci."},{"issue":"6797","key":"2721_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/35021086","volume":"406","author":"PJ Coopman","year":"2000","unstructured":"Coopman, P. J. et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406(6797), 742\u2013747 (2000).","journal-title":"Nature"},{"issue":"2","key":"2721_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/ijms22020592","volume":"22","author":"S Sender","year":"2021","unstructured":"Sender, S. et al. Precursor B-ALL cell lines differentially respond to SYK inhibition by entospletinib. Int. J. Mol. Sci. 22(2), 592 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"48","key":"2721_CR18","doi-asserted-by":"publisher","first-page":"83900","DOI":"10.18632\/oncotarget.19911","volume":"8","author":"P Gao","year":"2017","unstructured":"Gao, P. et al. Activated spleen tyrosine kinase promotes malignant progression of oral squamous cell carcinoma via mTOR\/S6 signaling pathway in an ERK1\/2-independent manner. Oncotarget 8(48), 83900\u201383912 (2017).","journal-title":"Oncotarget"},{"key":"2721_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae909","author":"M Kanehisa","year":"2024","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucl. Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2024).","journal-title":"Nucl. Acids Res."},{"issue":"11","key":"2721_CR20","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28(11), 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"issue":"1","key":"2721_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"2721_CR22","doi-asserted-by":"publisher","first-page":"W317","DOI":"10.1093\/nar\/gkab447","volume":"49","author":"D Bu","year":"2021","unstructured":"Bu, D. et al. KOBAS-i: Intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. Nucleic Acids Res. 49(W1), W317-w325 (2021).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"2721_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang, D. et al. SRplot: A free online platform for data visualization and graphing. PLoS ONE 18(11), e0294236 (2023).","journal-title":"PLoS ONE"},{"issue":"1","key":"2721_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/cancers12010250","volume":"12","author":"O Elaskalani","year":"2020","unstructured":"Elaskalani, O. et al. Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells. Cancers 12(1), 250 (2020).","journal-title":"Cancers"},{"issue":"1\u20132","key":"2721_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10585-018-9874-1","volume":"35","author":"AJ Gareau","year":"2018","unstructured":"Gareau, A. J. et al. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer. Clin. Exp. Metastasis 35(1\u20132), 25\u201335 (2018).","journal-title":"Clin. Exp. Metastasis"},{"issue":"6","key":"2721_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","volume":"33","author":"M Haemmerle","year":"2018","unstructured":"Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V. & Sood, A. K. The platelet lifeline to cancer: Challenges and opportunities. Cancer Cell 33(6), 965\u2013983 (2018).","journal-title":"Cancer Cell"},{"issue":"1","key":"2721_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","volume":"11","author":"M Schlesinger","year":"2018","unstructured":"Schlesinger, M. Role of platelets and platelet receptors in cancer metastasis. J. Hematol. Oncol. 11(1), 125 (2018).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"2721_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bbamcr.2014.10.022","volume":"1853","author":"MO Krisenko","year":"2015","unstructured":"Krisenko, M. O. & Geahlen, R. L. Calling in SYK: SYK\u2019s dual role as a tumor promoter and tumor suppressor in cancer. Biochem. Biophys. Acta. 1853(1), 254\u2013263 (2015).","journal-title":"Biochem. Biophys. Acta."},{"key":"2721_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4137\/CIN.S7226","volume":"10","author":"G Shin","year":"2011","unstructured":"Shin, G. et al. GENT: Gene expression database of normal and tumor tissues. Cancer Inform. 10, 149\u2013157 (2011).","journal-title":"Cancer Inform."},{"issue":"7391","key":"2721_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391), 603\u2013607 (2012).","journal-title":"Nature"},{"key":"2721_CR31","doi-asserted-by":"publisher","first-page":"204062072110108","DOI":"10.1177\/20406207211010875","volume":"12","author":"N Cooper","year":"2021","unstructured":"Cooper, N. et al. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Ther. Adv. Hematol. 12, 20406207211010876 (2021).","journal-title":"Ther. Adv. Hematol."},{"issue":"24","key":"2721_CR32","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1038\/onc.2009.99","volume":"28","author":"RM Larive","year":"2009","unstructured":"Larive, R. M. et al. Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell\u2013cell adhesion. Oncogene 28(24), 2337\u20132347 (2009).","journal-title":"Oncogene"},{"issue":"5","key":"2721_CR33","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.7314\/APJCP.2013.14.5.3001","volume":"14","author":"CL Peng","year":"2013","unstructured":"Peng, C. L. et al. Inhibitory effects of syk transfection on lung cancer cell invasion. Asian Pac. J. Cancer Prev. 14(5), 3001\u20133003 (2013).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2721_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jbior.2015.06.001","volume":"59","author":"GF Guidetti","year":"2015","unstructured":"Guidetti, G. F., Canobbio, I. & Torti, M. PI3K\/Akt in platelet integrin signaling and implications in thrombosis. Adv. Biol. Regul. 59, 36\u201352 (2015).","journal-title":"Adv. Biol. Regul."},{"key":"2721_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","volume":"698","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S. & Baradaran, B. The relation between PI3K\/AKT signalling pathway and cancer. Gene 698, 120\u2013128 (2019).","journal-title":"Gene"},{"issue":"2","key":"2721_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara, J. A. et al. PI3K\/Akt signalling pathway and cancer. Cancer Treat. Rev. 30(2), 193\u2013204 (2004).","journal-title":"Cancer Treat. Rev."},{"key":"2721_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/bs.podrm.2021.10.003","volume":"47","author":"MF Kabil","year":"2022","unstructured":"Kabil, M. F., Abo Dena, A. S. & El-Sherbiny, I. M. Ticagrelor. Profiles Drug Subst. Excip. Relat. Methodol. 47, 91\u2013111 (2022).","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"issue":"1","key":"2721_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ijc.28947","volume":"136","author":"S Gebremeskel","year":"2015","unstructured":"Gebremeskel, S., LeVatte, T., Liwski, R. S., Johnston, B. & Bezuhly, M. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int. J. Cancer 136(1), 234\u2013240 (2015).","journal-title":"Int. J. Cancer"},{"issue":"11","key":"2721_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080780","volume":"8","author":"Y Wang","year":"2013","unstructured":"Wang, Y. et al. Platelet P2Y12 is involved in murine pulmonary metastasis. PLoS ONE 8(11), e80780 (2013).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02721-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02721-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02721-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:06:11Z","timestamp":1747735571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02721-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2721"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02721-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental animals were housed and maintained in standard laboratory conditions according to the Guidelines for Animal Welfare in Experimental Animals (Issued by the Ministry of Science and Technology of the People\u2019s Republic of China in 2006) and the agreement of the Institutional Animal Care and Use Committee of Jinggangshan University (2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17457"}}